Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | PNLIP | P16233 | 1/20 | 0.41 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475225 | 0.93 | MEN1 (0.41) | MAPTMEN1KMT2ALMNANR1I2 | |
| SCHEMBL6476218 | 0.93 | MAPT (0.47) | MAPTMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL6481903 | 0.86 | TERT (0.42) | MAPTMEN1KMT2ALMNAHDAC6 | |
| SCHEMBL6477119 | 0.84 | TERT (0.40) | MAPTHDAC6HDAC1TERTGAA | |
| SCHEMBL20569457 | 0.83 | LMNA (0.46) | MAPTMEN1KMT2ALMNANR1I2 | |
| SCHEMBL6483212 | 0.83 | CYP19A1 (0.40) | MAPTMEN1KMT2ALMNACYP3A4 | |
| SCHEMBL6476169 | 0.82 | MEN1 (0.42) | MAPTMEN1KMT2ALMNANR1I2 | |
| SCHEMBL6476050 | 0.80 | KMT2A (0.43) | MAPTMEN1KMT2ALMNANR1I2 | |
| SCHEMBL1669 | 0.80 | TERT (0.64) | MAPTMEN1KMT2ALMNANR1I2 | |
| SCHEMBL6481905 | 0.80 | MAPT (0.42) | MAPTMEN1KMT2ALMNANR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4696376-A2 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | Topadur Pharma AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-3630769-B1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| US-20240360136-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2024-10-31 | — | — | US | disclosed |
| CN-118063458-A | Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11905293-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2024-02-20 | — | — | US | disclosed |
| CN-110621676-B | Dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20220073529-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-03-10 | — | — | US | disclosed |
| US-20220073529-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-03-10 | — | — | US | disclosed |
| US-11155558-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2021-10-26 | — | — | US | disclosed |
| US-11155558-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2021-10-26 | — | — | US | disclosed |
| US-20200181149-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2020-06-11 | — | — | US | disclosed |
| US-20200181149-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2020-06-11 | — | — | US | disclosed |
| EP-3630769-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | Topadur Pharma AG (CH) | 2020-04-08 | — | — | EP | disclosed |
| CN-110621676-A | Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2019-12-27 | — | — | CN | disclosed |
| WO-2018215433-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2018-11-29 | — | — | WO | disclosed |
| US-6962911-B2 | Pyrrolopyrimidinone derivatives, process of preparation and use | SK CHEMICALS CO., LTD. (KR) | 2005-11-08 | — | — | US | disclosed |
| EP-1257553-B1 | PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE | SK CHEMICALS CO LTD (KR) | 2004-05-26 | — | — | EP | disclosed |
| US-20030171361-A1 | Pyrrolopyrimidinone derivatives, process of preparation and use | SK CHEMICALS CO., LTD. (KR) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171361-A1 | Pyrrolopyrimidinone derivatives, process of preparation and use | CYP2C19, DHPS, SDHA | MAPT 1845/4885MEN1 2829/4885KMT2A 4373/4885 |
| US-20220073529-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE1A, PDE2A | MAPT 4060/4885MEN1 2061/4885KMT2A 3418/4885 |
| US-11155558-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | PDE7A, GNAO1, PDE3A | MAPT 4871/4885MEN1 2283/4885KMT2A 4417/4885 |
| US-20200181149-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, PDE3A, PDE9A | MAPT 4872/4885MEN1 2541/4885KMT2A 4503/4885 |
| US-11905293-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | PDE5A, PDE1A, PDE2A | MAPT 4060/4885MEN1 2061/4885KMT2A 3418/4885 |
| US-20240360136-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE1A, PDE2A | MAPT 4060/4885MEN1 2061/4885KMT2A 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.